carbobenzoxyphenylalanyl-phenylalanyl-glycine: RN given refers to (D)-Phe-(L)PheGly cpd; blocking group is on the amino-terminus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 474878 |
| SCHEMBL ID | 10521480 |
| MeSH ID | M0144885 |
| Synonym |
|---|
| 75539-79-6 |
| carbobenzoxy-phe-phe-gly |
| z-phe-phe-gly |
| cbz-phe-phe-gly |
| benzyloxycarbonyl-phe-phe-gly |
| glycine, n-(n-(n-((phenylmethoxy)carbonyl)-d-phenylalanyl)-l-phenylalanyl)- |
| virus replication inhibitory peptide ppg |
| 2-[[(2s)-2-[[(2r)-2-(benzyloxycarbonylamino)-3-phenyl-propanoyl]amino]-3-phenyl-propanoyl]amino]acetic acid |
| z-d-phe-l-phe-gly |
| carbobenzoxy-d-phe-l-phe-gly |
| carbobenzoxyphenylalanyl-phenylalanyl-glycine |
| 2-[[(2s)-3-phenyl-2-[[(2r)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]propanoyl]amino]acetic acid |
| 2-[[(2s)-1-oxo-2-[[(2r)-1-oxo-3-phenyl-2-(phenylmethoxycarbonylamino)propyl]amino]-3-phenylpropyl]amino]acetic acid |
| 2-[[(2s)-3-phenyl-2-[[(2r)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]propanoyl]amino]ethanoic acid |
| A811423 |
| SCHEMBL10521480 |
| glycine, n-[(phenylmethoxy)carbonyl]-d-phenylalanyl-l-phenylalanyl- |
| carbobenzoxy-d-phenylalanyl-l-phenylalanylglycine |
| mfcd00063351 |
| z-d-phe-phe-gly-oh |
| n-{2-[(2-{[(benzyloxy)(hydroxy)methylidene]amino}-1-hydroxy-3-phenylpropylidene)amino]-1-hydroxy-3-phenylpropylidene}glycine |
| DTXSID00997002 |
| ((benzyloxy)carbonyl)-d-phenylalanyl-l-phenylalanylglycine |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.32) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||